STOCK TITAN

Alnylam (NASDAQ: ALNY) EVP receives new options and RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ALNYLAM PHARMACEUTICALS, INC. executive Bryan Supran, EVP, CLO and Secretary, reported equity awards consisting of stock options and restricted stock units. He received stock options for 3,381 shares at an exercise price of $0.00 per share, and a grant of 1,539 shares of common stock represented by restricted stock units.

The RSUs vest over three years, with one third vesting on each of the first, second and third anniversaries of the grant date, conditioned on continued service. The stock options vest 25% on the first anniversary of the grant date, with the remainder vesting in equal quarterly installments until the fourth anniversary, also subject to continuous service.

Positive

  • None.

Negative

  • None.
Insider SUPRAN BRYAN
Role EVP, CLO and Secretary
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,381 $0.00 --
Grant/Award Common Stock 1,539 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,381 shares (Direct); Common Stock — 14,565 shares (Direct)
Footnotes (1)
  1. These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SUPRAN BRYAN

(Last) (First) (Middle)
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, CLO and Secretary
3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/02/2026 A 1,539(1) A $0.0 14,565 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $325.07 03/02/2026 A 3,381 (2) 03/02/2036 Common Stock 3,381 $0.0 3,381 D
Explanation of Responses:
1. These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
2. The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
By: Brett Budzinski, Attorney-in-Fact For: Bryan A. Supran 03/04/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ALNY executive Bryan Supran report on this Form 4 for ALNY?

Bryan Supran reported acquiring stock options for 3,381 shares and 1,539 shares of common stock via restricted stock units. Both awards were granted at no cash cost and are subject to multi-year vesting tied to his continued service with Alnylam.

How many stock options were granted to ALNY executive Bryan Supran and how do they vest?

He was granted stock options for 3,381 shares of Alnylam common stock. Twenty-five percent vests on the first anniversary of the grant date, with the remaining shares vesting in equal quarterly installments until the fourth anniversary, subject to continued employment.

What is the size and structure of the restricted stock unit grant to ALNY’s Bryan Supran?

Bryan Supran received 1,539 restricted stock units, each representing one share of Alnylam common stock. The RSUs vest over three years, with one third vesting on each of the first, second and third anniversaries of the grant date, contingent on continuous service.

Did Bryan Supran buy or sell ALNY common stock on the open market in this Form 4?

The filing reflects equity awards, not open-market trades. Supran acquired stock options and restricted stock units at a price of $0.00 per share as compensation, with vesting over time based on his continued service with Alnylam Pharmaceuticals.

Are the equity awards to ALNY executive Bryan Supran directly owned and what ownership type is reported?

The reported stock options and restricted stock units are listed as directly owned by Bryan Supran. The ownership code is shown as direct, with no footnotes indicating that another entity, such as a trust or LLC, holds voting or investment authority over these awards.

What conditions must be met for Bryan Supran to receive all ALNY RSU and option shares?

Both RSU and option vesting depend on his continuous service with Alnylam. RSUs vest in three equal annual installments over three years, while options vest 25% after one year and the rest quarterly through year four, assuming ongoing employment on each vesting date.